BRANMOOR
THURSDAY · 14 MAY 2026

FDA Recall D-0058-2023

Viatris Inc · Canonsburg, PA

Class I — life-threatening Terminated 462 days on record

Highest impact — Class I recall — FDA determination of strong likelihood of serious adverse health consequence or death.

Product

Octreotide Acetate Injection 500 mcg/mL, 10 x 1 mL Single-Dose Unit-of-Use Syringes, For Subcutaneous or Intravenous Use, Rx Only, Manufactured for: Mylan Institutional LLC, Morgantown, WV 26505 U.S.A., Made in Italy, NDC: 67457-246-00 (syringe), 67457-246-01 (carton).

Lot / code: Lot #: AJ21002, Exp. 03/2024

Quantity: 22400 syringes

Reason for recall

Presence of Particulate Matter: Product complaint for the presence of glass particles in a syringe.

Recall record

Recall number
D-0058-2023
Classification
Class I
Status
Terminated
Voluntary or mandated
Voluntary: Firm initiated
Firm notification
Letter
Distribution
Nationwide in the USA
Recall initiated
2022-10-07
Classified by FDA Center
2022-11-08
FDA published
2022-11-16
Terminated
2024-01-12
Recalling firm
Viatris Inc
Firm location
Canonsburg, PA

Drug identification

Brand name(s)
OCTREOTIDE ACETATE
Generic name(s)
OCTREOTIDE ACETATE
Manufacturer(s)
Mylan Institutional LLC
NDC(s)
67457-239, 67457-245, 67457-246
Route(s)
INTRAVENOUS, SUBCUTANEOUS

‹ All recalls